Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:5409 |
Name | lung small cell carcinoma |
Definition | A lung carcinoma that has_material_basis_in primitive-appearing cells that are smaller than normal cells and is located_in the lung. |
Source | DiseaseOntology.org |
Alt Ids | DOID:0050875 |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung small cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Alisertib | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Alisertib + Paclitaxel | lung small cell carcinoma | not applicable | detail... |
RET wild-type | Vandetanib | lung small cell carcinoma | sensitive | detail... |
RET M918T | Ponatinib | lung small cell carcinoma | sensitive | detail... |
RET wild-type | Ponatinib | lung small cell carcinoma | sensitive | detail... |
RET M918T | Vandetanib | lung small cell carcinoma | sensitive | detail... |
Unknown unknown | Etoposide + NVP-ADW742 | lung small cell carcinoma | not applicable | detail... |
FGFR1 amp | Debio 1347 | lung small cell carcinoma | sensitive | detail... |
PDGFRA amp | Ponatinib | lung small cell carcinoma | sensitive | detail... |
Unknown unknown | Sunitinib | lung small cell carcinoma | not applicable | detail... |
RB1 loss | Trilaciclib | lung small cell carcinoma | resistant | detail... |
RB1 loss | Topotecan + Trilaciclib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | AZD4547 | lung small cell carcinoma | sensitive | detail... |
PIK3CA act mut | Navitoclax + Pictilisib | lung small cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | Navitoclax + Pictilisib | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Doxorubicin + SLCB050 | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | BDA-366 | lung small cell carcinoma | not applicable | detail... |
FGFR1 amp | RO4987655 | lung small cell carcinoma | no benefit | detail... |
FGFR1 amp | RO5126766 | lung small cell carcinoma | no benefit | detail... |
FGFR1 amp | Selumetinib | lung small cell carcinoma | no benefit | detail... |
Unknown unknown | STA-8666 | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Ganetespib | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Carboplatin + STA-8666 | lung small cell carcinoma | not applicable | detail... |
FGFR1 rearrange | AZD4547 | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | E7090 | lung small cell carcinoma | sensitive | detail... |
Unknown unknown | Bevacizumab + Cisplatin + Etoposide | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Vandetanib | lung small cell carcinoma | no benefit | detail... |
Unknown unknown | Talazoparib | lung small cell carcinoma | not applicable | detail... |
FGFR1 amp | AZD4547 + Buparlisib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | GSK3052230 | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | Cisplatin + Etoposide + GSK3052230 | lung small cell carcinoma | sensitive | detail... |
Unknown unknown | Sacituzumab govitecan-hziy | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Doxorubicin + Lurbinectedin | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | T-3775440 | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Nivolumab | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Roniciclib | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Carboplatin + Etoposide + Roniciclib | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Atezolizumab + Carboplatin + Etoposide | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Pembrolizumab | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Sabatolimab + Spartalizumab | lung small cell carcinoma | not applicable | detail... |
ATM D2725G | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
ATM S333F | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
ATM V410A | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | Mogamulizumab + Nivolumab | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Olaparib + Temozolomide | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | DT2216 + Venetoclax | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Carboplatin + Durvalumab + Etoposide | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Cisplatin + Durvalumab + Etoposide | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | MGC018 | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Cisplatin + Etoposide + Roniciclib | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | AZD2811 | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Cisplatin + Etoposide + Tislelizumab | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | Carboplatin + Etoposide + Tislelizumab | lung small cell carcinoma | not applicable | detail... |
Unknown unknown | AMG 119 | lung small cell carcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Recruiting | USA | 0 |
NCT00926640 | Phase I | Belinostat + Cisplatin + Etoposide | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | Completed | USA | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | 1 |
NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Active, not recruiting | USA | 0 |
NCT01450761 | Phase III | Cisplatin Ipilimumab Carboplatin Etoposide | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Completed | USA | CAN | 32 |
NCT01579929 | Phase I | Cisplatin + Etoposide + Sonidegib | Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Completed | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | 6 |
NCT01638546 | Phase II | Temozolomide Veliparib | Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | Completed | USA | 0 |
NCT01642251 | Phase Ib/II | Cisplatin + Etoposide Veliparib | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01722292 | Phase Ib/II | Taladegib Carboplatin + Etoposide | A Study of LY2940680 in Small Cell Lung Cancer | Terminated | USA | 1 |
NCT01737502 | Phase Ib/II | Auranofin + Sirolimus | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | 2 |
NCT01859741 | Phase Ib/II | Cisplatin Etoposide Carboplatin Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) | Terminated | USA | 0 |
NCT01892046 | Phase I | Carboplatin SNX-5422 Paclitaxel | Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | Completed | USA | 0 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | CAN | 6 |
NCT02034123 | Phase I | GSK2879552 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | Terminated | USA | 2 |
NCT02038647 | Phase II | Paclitaxel Alisertib | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | Completed | USA | CAN | 8 |
NCT02100007 | Phase Ib/II | ME-344 + Topotecan | ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors | Terminated | USA | 1 |
NCT02152059 | Phase II | Nintedanib | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | Withdrawn | CAN | 0 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | 1 |
NCT02161419 | Phase II | Roniciclib | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer | Terminated | USA | 8 |
NCT02200757 | Phase II | Aldoxorubicin Topotecan | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | Unknown status | USA | 2 |
NCT02247349 | Phase Ib/II | BMS-986012 BMS-986012 + Nivolumab | BMS-986012 in Relapsed/Refractory SCLC | Active, not recruiting | USA | CAN | 5 |
NCT02250885 | Phase II | Selinexor | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Completed | USA | 0 |
NCT02261805 | Phase Ib/II | Aldoxorubicin + Ganetespib | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | Terminated | USA | 0 |
NCT02289690 | Phase I | Carboplatin + Etoposide + Veliparib | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | Completed | USA | CAN | 10 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02351505 | Phase II | Selinexor | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02359019 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy | Active, not recruiting | USA | 0 |
NCT02402920 | Phase I | Carboplatin + Etoposide + Pembrolizumab Cisplatin | Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Recruiting | USA | CAN | 4 |
NCT02446704 | Phase Ib/II | Olaparib Temozolomide | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | Active, not recruiting | USA | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Active, not recruiting | USA | 8 |
NCT02472977 | Phase Ib/II | Nivolumab Ulocuplumab | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | Terminated | USA | 1 |
NCT02481830 | Phase III | Amrubicin Nivolumab Topotecan | Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer | Active, not recruiting | USA | 24 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02489903 | Phase II | Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel | RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens | Active, not recruiting | USA | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT02499770 | Phase Ib/II | Carboplatin + Etoposide Trilaciclib | G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | Completed | USA | 6 |
NCT02514447 | Phase Ib/II | Trilaciclib Topotecan | Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | Active, not recruiting | USA | 7 |
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Recruiting | USA | 5 |
NCT02537418 | Phase I | Cisplatin + Etoposide Durvalumab Tremelimumab | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens | Active, not recruiting | CAN | 0 |
NCT02538666 | Phase III | Ipilimumab Nivolumab | A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) | Active, not recruiting | USA | CAN | 30 |
NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02579226 | Phase I | Irinotecan AZD2811 | A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | 1 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | CAN | 19 |
NCT02631733 | Phase I | Irinotecan + Veliparib | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Suspended | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02649673 | Phase Ib/II | LCL161 + Topotecan | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | Active, not recruiting | USA | 0 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | 5 |
NCT02671955 | Phase I | JNJ-61610588 | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02674568 | Phase II | Rovalpituzumab Tesirine | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) | Completed | 0 | |
NCT02701400 | Phase II | Tavolimab + Tremelimumab | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | Completed | USA | 0 |
NCT02734004 | Phase Ib/II | Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) | Active, not recruiting | USA | 6 |
NCT02735980 | Phase II | Prexasertib | A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer | Completed | USA | 9 |
NCT02748889 | Phase Ib/II | Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02763579 | Phase III | Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133) | Active, not recruiting | USA | 20 |
NCT02815592 | Phase Ib/II | Etoposide BMS-986012 + Cisplatin + Etoposide BMS-986012 + Carboplatin + Etoposide | Trial of BMS-986012 in Combination With Platinum and Etoposide | Active, not recruiting | 1 | |
NCT02819999 | Phase I | Cisplatin + Etoposide + Rovalpituzumab Tesirine Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02874664 | Phase I | Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT02899728 | Phase II | Carboplatin + Cisplatin + Etoposide Cediranib + Olaparib | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Recruiting | USA | 0 |
NCT02934503 | Phase II | Carboplatin + Cisplatin + Etoposide + Pembrolizumab | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | Completed | USA | 0 |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Active, not recruiting | USA | 1 |
NCT02963090 | Phase II | Pembrolizumab + Topotecan Pembrolizumab | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03026166 | Phase I | Ipilimumab + Nivolumab + Rovalpituzumab Tesirine Nivolumab + Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | Terminated | USA | 4 |
NCT03033511 | Phase III | Dexamethasone + Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU) | Terminated | USA | CAN | 39 |
NCT03041311 | Phase II | Atezolizumab + Carboplatin + Etoposide + Trilaciclib Atezolizumab + Carboplatin + Etoposide | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC) | Active, not recruiting | USA | 6 |
NCT03043599 | Phase Ib/II | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03043872 | Phase III | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Etoposide Carboplatin + Cisplatin + Etoposide | Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian) | Active, not recruiting | USA | 22 |
NCT03061812 | Phase III | Rovalpituzumab Tesirine Topotecan | Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE) | Completed | USA | CAN | 31 |
NCT03066778 | Phase III | Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | Active, not recruiting | USA | CAN | 17 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03080311 | Phase I | APG-1252 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | Completed | USA | 0 |
NCT03085849 | Phase I | Durvalumab + Guadecitabine + Tremelimumab | SGI-110 Plus Durvalumab/Tremelimumab in SCLC | Completed | USA | 0 |
NCT03092934 | Phase Ib/II | LY3295668 | A Study of AK-01 (LY3295668) in Solid Tumors | Completed | CAN | 0 |
NCT03116971 | Phase Ib/II | Cisplatin + Etoposide + MSC2490484A MSC2490484A | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | Terminated | USA | CAN | 11 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 3 |
NCT03179436 | Phase Ib/II | MK-1308 + Pembrolizumab MK-1308 | Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | Recruiting | USA | CAN | 13 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) | Recruiting | USA | 0 |
NCT03319940 | Phase I | AMG 757 | Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer | Recruiting | USA | 8 |
NCT03325816 | Phase Ib/II | Nivolumab | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03334487 | Phase III | Dexamethasone + Rovalpituzumab Tesirine | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer | Withdrawn | USA | CAN | 5 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03363893 | Phase Ib/II | ICEC0942 Fulvestrant + ICEC0942 | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Recruiting | USA | 1 |
NCT03365791 | Phase II | LAG525 Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03366103 | Phase Ib/II | Navitoclax + Vistusertib | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | Recruiting | USA | 0 |
NCT03371979 | Phase Ib/II | Pegzilarginase + Pembrolizumab | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | Completed | USA | 1 |
NCT03382561 | Phase II | Cisplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab Cisplatin + Etoposide Carboplatin + Etoposide | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer | Active, not recruiting | USA | 0 |
NCT03402880 | Phase II | Epacadostat + Pembrolizumab | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03406715 | Phase II | Ad.p53-DC vaccine + Ipilimumab + Nivolumab | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | Recruiting | USA | 0 |
NCT03460977 | Phase I | PF-06821497 | PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Recruiting | USA | 3 |
NCT03509012 | Phase I | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) | Active, not recruiting | USA | 4 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |
NCT03532880 | Phase I | Olaparib | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03554473 | Phase Ib/II | M7824 + Topotecan M7824 + Temozolomide M7824 | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | Recruiting | USA | 0 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Active, not recruiting | USA | 0 |
NCT03575793 | Phase Ib/II | Ipilimumab + Nivolumab + Plinabulin Ipilimumab + Nivolumab | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03639194 | Phase I | ABBV-011 + ABBV-181 ABBV-011 | A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03662074 | Phase II | Gemcitabine + Nivolumab | Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03670056 | Phase II | Ipilimumab + Nivolumab | A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy | Recruiting | USA | 0 |
NCT03672773 | Phase II | Talazoparib + Temozolomide | Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03703297 | Phase III | Durvalumab Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) | Recruiting | USA | CAN | 18 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Recruiting | USA | 5 |
NCT03728361 | Phase II | Nivolumab + Temozolomide | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | Recruiting | USA | 0 |
NCT03752398 | Phase I | XmAb23104 | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Recruiting | USA | 0 |
NCT03811002 | Phase II | Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide | Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | 0 |
NCT03830918 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | Recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Recruiting | USA | 0 |
NCT03879798 | Phase Ib/II | DS-3201b + Irinotecan | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03896503 | Phase II | Topotecan Berzosertib + Topotecan | Topotecan With or Without M6620 in Treating Patients With Relapsed Small Cell Lung Cancer or Extrapulmonary Small Cell Cancer | Recruiting | USA | 0 |
NCT03898791 | Phase Ib/II | LY3295668 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | Completed | USA | 7 |
NCT03913455 | Phase II | Carboplatin + Guadecitabine | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03923270 | Phase I | Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Active, not recruiting | USA | 4 |
NCT03958045 | Phase II | Nivolumab + Rucaparib | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | Recruiting | USA | 0 |
NCT03963414 | Phase I | Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Etoposide | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | Recruiting | USA | 0 |
NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Suspended | USA | 0 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT04010357 | Phase II | Abemaciclib | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | Recruiting | USA | 0 |
NCT04032704 | Phase II | Ladiratuzumab vedotin | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Recruiting | USA | 5 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab | Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors | Recruiting | USA | 4 |
NCT04101357 | Phase Ib/II | BNT411 Atezolizumab + BNT411 + Carboplatin + Etoposide | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Recruiting | USA | 3 |
NCT04122625 | Phase Ib/II | Debio 1143 + Nivolumab | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Recruiting | USA | 2 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Active, not recruiting | USA | 0 |
NCT04165330 | Phase Ib/II | Anlotinib + Nivolumab | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | Recruiting | USA | 0 |
NCT04170946 | Phase I | Talazoparib | Talazoparib and Thoracic RT for ES-SCLC | Recruiting | CAN | 0 |
NCT04173325 | Phase I | Nivolumab Irinotecan + Nivolumab | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04209595 | Phase Ib/II | PLX038 + Rucaparib | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | Recruiting | USA | 0 |
NCT04210037 | Phase Ib/II | APG-1252 + Paclitaxel | Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | Recruiting | USA | 1 |
NCT04256421 | Phase III | Atezolizumab + Carboplatin + Etoposide + MTIG7192A Atezolizumab + Carboplatin + Etoposide | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02) | Recruiting | USA | 23 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) | Recruiting | USA | 0 |
NCT04334941 | Phase II | Atezolizumab + Talazoparib Atezolizumab | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | Recruiting | USA | 0 |
NCT04350463 | Phase II | CC-90011 + Nivolumab | A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | Recruiting | USA | 5 |
NCT04373369 | Phase II | Atezolizumab + Vorolanib | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04397003 | Phase II | Carboplatin + Durvalumab + Etoposide Durvalumab + Tremelimumab Durvalumab + Personalized cancer vaccine + Tremelimumab | Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer | Not yet recruiting | USA | 0 |
NCT04402788 | Phase II | Atezolizumab Atezolizumab + Radiotherapy | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Recruiting | USA | 0 |
NCT04422210 | Phase I | Atezolizumab + Venetoclax Atezolizumab + Carboplatin + Etoposide + Venetoclax | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). | Active, not recruiting | USA | 4 |
NCT04423029 | Phase Ib/II | DF6002 + Pembrolizumab DF6002 | Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications | Recruiting | USA | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Recruiting | USA | CAN | 2 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04538378 | Phase II | Durvalumab + Olaparib | Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT04543916 | Phase Ib/II | Irinotecan + Venetoclax | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | Withdrawn | 0 | |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Recruiting | USA | 0 |
NCT04560972 | Phase I | Atezolizumab + Carboplatin + Etoposide + LB-100 Atezolizumab + LB-100 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | Not yet recruiting | USA | 0 |
NCT04607954 | Phase II | Durvalumab + Topotecan | Durvalumab and Topotecan for the Treatment of Relapsed or Refractory Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04610658 | Phase Ib/II | Ipilimumab + Lurbinectedin + Nivolumab | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | Recruiting | USA | 0 |
NCT04610684 | Phase II | Atezolizumab Atezolizumab + Carboplatin + Etoposide | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | Recruiting | USA | 0 |
NCT04624204 | Phase III | Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) | Recruiting | USA | 10 |
NCT04696575 | Phase II | Atezolizumab + Carboplatin + Etoposide + Lamivudine Atezolizumab + Lamivudine | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | Not yet recruiting | USA | 0 |
NCT04701307 | Phase II | Dostarlimab + Niraparib | Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas | Recruiting | USA | 0 |
NCT04728230 | Phase Ib/II | Carboplatin + Durvalumab + Etoposide + Olaparib | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | Recruiting | USA | 0 |
NCT04768296 | Phase II | Berzosertib + Topotecan | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | Not yet recruiting | USA | 1 |